| Cardiac myosin activation: a potential therapeutic approach for systolic heart failure FI Malik, JJ Hartman, KA Elias, BP Morgan, H Rodriguez, K Brejc, ... Science 331 (6023), 1439-1443, 2011 | 648 | 2011 |
| Structure, function, and therapeutic use of IgM antibodies BA Keyt, R Baliga, AM Sinclair, SF Carroll, MS Peterson Antibodies 9 (4), 53, 2020 | 170 | 2020 |
| Kinetic consequences of covalent linkage of DNA binding polyamides R Baliga, EE Baird, DM Herman, C Melander, PB Dervan, DM Crothers Biochemistry 40 (1), 3-8, 2001 | 75 | 2001 |
| Cell-free translation of peptides and proteins: from high throughput screening to clinical production CJ Murray, R Baliga Current opinion in chemical biology 17 (3), 420-426, 2013 | 73 | 2013 |
| RecA. oligonucleotide filaments bind in the minor groove of double-stranded DNA. R Baliga, JW Singleton, PB Dervan Proceedings of the National Academy of Sciences 92 (22), 10393-10397, 1995 | 71 | 1995 |
| Engineering toward a bacterial “endoplasmic reticulum” for the rapid expression of immunoglobulin proteins D Groff, S Armstrong, PJ Rivers, J Zhang, J Yang, E Green, J Rozzelle, ... MAbs 6 (3), 671-678, 2014 | 69 | 2014 |
| On the kinetics of distamycin binding to its target sites on duplex DNA R Baliga, DM Crothers Proceedings of the National Academy of Sciences 97 (14), 7814-7818, 2000 | 67 | 2000 |
| Discovery of the first potent and selective inhibitor of centromere-associated protein E: GSK923295 X Qian, A McDonald, HJ Zhou, ND Adams, CA Parrish, KJ Duffy, DM Fitch, ... ACS medicinal chemistry letters 1 (1), 30-34, 2010 | 64 | 2010 |
| RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates G Yin, HT Stephenson, J Yang, X Li, SM Armstrong, TH Heibeck, C Tran, ... Scientific Reports 7 (1), 3026, 2017 | 48 | 2017 |
| In vitro Fab display: a cell-free system for IgG discovery RL Stafford, ML Matsumoto, G Yin, Q Cai, JJ Fung, H Stephenson, A Gill, ... Protein engineering, design & selection 27 (4), 97-109, 2014 | 45 | 2014 |
| Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use CD Thanos, R Baliga, K Penta, A Gill, G Yin, E Zimmerman US Patent 9,764,039, 2017 | 34 | 2017 |
| Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use CD Thanos, L McEvoy, G Yin, K Penta, R Baliga, S Bajad, S Pollitt, ... US Patent 9,738,724, 2017 | 31 | 2017 |
| Multimeric bispecific binding molecules specific for CD20 and CD3 BA Keyt, O Duramad, BTY Wang, R Baliga, F Zhang US Patent 10,787,520, 2020 | 24 | 2020 |
| Modified J-chain B Keyt, LG Presta, F Zhang, R Baliga US Patent 10,400,038, 2019 | 22 | 2019 |
| The kinetic basis for sequence discrimination by distamycin A R Baliga, DM Crothers Journal of the American Chemical Society 122 (47), 11751-11752, 2000 | 20 | 2000 |
| Tumor necrosis factor (TNF) superfamily receptor IgM antibodies and uses thereof BTY Wang, MA Schwarzer, BA Keyt, R Baliga US Patent 9,938,347, 2018 | 19 | 2018 |
| Binding molecules with modified J-chain BA Keyt, LG Presta, R Baliga US Patent 11,639,389, 2023 | 17 | 2023 |
| Modified J-chain B Keyt, LG Presta, F Zhang, R Baliga US Patent 11,555,075, 2023 | 16 | 2023 |
| Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof BTY Wang, MA Schwarzer, BA Keyt, R Baliga US Patent 10,689,449, 2020 | 16 | 2020 |
| Multi-valent hepatitis B virus antigen binding molecules and uses thereof SF Carroll, R Baliga, D Ng, B Keyt US Patent 10,604,559, 2020 | 16 | 2020 |
